- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03232580
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis (Annexin 03)
Phase II Study of 99mTc-rhAnnexin V-128 Radionuclide Imaging in Patients With Clinical Suspicion or Confirmed Diagnosis of Spondyloarthritis (SpA)
This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.
Overall, it was planned to recruit 20 adults with suspected or confirmed SpA. First, 5 patients were enrolled into a "proof of concept" phase, to assess the imaging potential of 99mTc-rhAnnexin V-128 in terms of imaging quality, disease-lesion radiotracer uptake and medical relevance. Based on these results the Data Monitoring Committee (DMC) was to decide whether to terminate the study or whether to continue and enroll the next 15 planned patients.
Study Overview
Detailed Description
The study was prematurely terminated by the sponsor after the first 5 patients completed the PoC phase based on strategic considerations.
Novartis acquired Advanced Accelerator Applications SA.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For the first 5 patients enrolled in the POC part:
1. Patients with clinical suspicion or confirmed diagnosis of SpA, based on the ASA criteria with active symptoms including back, hip or buttock pain prior to:
- A change in NSAID therapy or
- A change in non-biologic DMARD or
- A start of non-biologic DMARD.
For the next 15 patients enrolled in the Phase II part:
Patients with clinical suspicion or confirmed diagnosis of SpA, based on the ASAS criteria with active symptoms including back, hip or buttock pain prior to:
- A change in NSAIDs therapy
- A change in non-biologic DMARD
- A start of non-biologic DMARD
- A start of biologic DMARD
For all patients:
- Age over 18 years old.
- Signed Informed Consent Form
Exclusion Criteria:
- Pregnancy or lactation
- Liver impairment (ALT, AST or Bilirubin > 2 ULN) at screening visit or baseline
- Kidney impairment (serum creatinine > 1.5 mg/dL)
- History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
- Known hypersensitivity to the investigational drug or any of its components
- Contraindication(s) to the MRI procedure (claustrophobia, prosthetic valve, pacemaker, inability to lie still in a supine position)
- Participation to another clinical trial within 4 weeks before study inclusion except for patients who have participated or who are currently participating in an interventional study without any study drug administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: rhAnnexin V-128
All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
|
All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
99mTc-rhAnnexin V-128 Uptake
Time Frame: 60 minutes and 120 minutes post investigational product adminstration
|
In order to asses 99mTc-rhAnnexin V-128 magnitude and dynamic range of uptake within areas affected by inflammation, Single-Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) scans were interpreted and graded by at least two independent experienced nuclear medicine physicians blinded from clinical data and other imagings modality results. Uptake compared with background (e.g. physiological liver uptake) were assessed for each affected area by nuclear medicine physicians using a 4-grade scoring system (e.g. 0, none; 1, mild or present but < to background uptake; 2, moderate or = to background uptake; 3, intense or > to background uptake). Only descriptive analysis performed. |
60 minutes and 120 minutes post investigational product adminstration
|
99mTc-rhAnnexin V-128 Uptake Adjudication
Time Frame: 60 minutes and 120 minutes post investigational product adminstration
|
In order to asses 99mTc-rhAnnexin V-128 magnitude and dynamic range of uptake within areas affected by inflammation, Single-Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) scans were interpreted and graded by at least two independent experienced nuclear medicine physicians blinded from clinical data and other imagings modality results. In case of discrepancies between the different readers, an adjudication process based on consensus was put in place in order to obtain one final outcome for each area. Adjudication results were categorized as Positive or Negative. Only descriptive analysis performed. |
60 minutes and 120 minutes post investigational product adminstration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Psoriatic arthritis
- Inflammatory bowel disease
- Ankylosing Spondylitis
- Ankylosing Spondyloarthritis
- Suspicion or confirmed diagnosis of Spondyloarthritis
- Ankylosing Spondylarthritis
- Rheumatoid Spondylitis
- Spondylarthritis Ankylopoietica
- Spondylitis Ankylopoietica
- Spondyloarthritis Ankylopoietica
- Autoimmune systemic rheumatic disease
- Undifferentiated spondyloarthropathy.
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAA-Annexin-03
- CAAA113A22201 (OTHER: Novartis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondyloarthritis
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
-
Merck Sharp & Dohme LLCCompletedSpondyloarthritisCzechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
Novartis PharmaceuticalsRecruitingNon-radiographic Axial SpondyloarthritisBelgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingSpondyloarthritis | Spondyloarthritis, AxialItaly
-
UCB BIOSCIENCES GmbHCompletedAxial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpAUnited States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Healthcare PharmaceuticalsRecruitingSpondyloarthritis, AxialBangladesh
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingSpondyloarthritis, AxialFrance
Clinical Trials on rhAnnexin V-128
-
Advanced Accelerator ApplicationsTerminated
-
Advanced Accelerator ApplicationsTerminatedRheumatoid Arthritis | Ankylosing SpondylitisSwitzerland
-
Advanced Accelerator ApplicationsTerminatedBreast Cancer | Doxorubicin Induced CardiomyopathyCanada
-
Advanced Accelerator ApplicationsAtreus Pharmaceuticals CorporationCompleted
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedAcute Lung Injury | Chronic Obstructive Pulmonary Disease (COPD)United States
-
Institut National de la Santé Et de la Recherche...Advanced Accelerator ApplicationsTerminatedThrombosis | EndocarditisFrance
-
Assistance Publique - Hôpitaux de ParisWithdrawnCarotid Atherosclerosis | Atherosclerotic Plaque
-
TakedaTerminatedDiabetic Neuropathies
-
TakedaCompletedDiabetic NeuropathiesUnited States, Canada
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid MalignanciesUnited States, Spain